MARKET

NERV

NERV

Minerva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.840
+0.170
+10.18%
Closed 18:14 09/16 EDT
OPEN
1.670
PREV CLOSE
1.670
HIGH
1.875
LOW
1.630
VOLUME
742.35K
TURNOVER
--
52 WEEK HIGH
4.115
52 WEEK LOW
1.540
MARKET CAP
78.61M
P/E (TTM)
-2.2464
1D
5D
1M
3M
1Y
5Y
3 Downgraded Stocks to Sell in a Shaky Market
StockNews.com · 22h ago
BRIEF-Minerva Neurosciences Names Ramana Kuchibhatla Senior Vice President
reuters.com · 09/08 13:03
Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva's lead program, rolupe...
Globe Newswire · 09/08 12:30
Highland Capital Management Fund Advisors, L.p. ...
GuruFocus News · 08/24 15:38
Cormorant Asset Management, LP Buys BioAtla Inc, Monte Rosa Therapeutics Inc, ALX Oncology ...
GuruFocus News · 08/24 13:38
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2)
Benzinga · 08/03 11:55
Stocks That Hit 52-Week Lows On Monday
    Monday morning, 34 companies reached new 52-week lows.
Benzinga · 08/02 14:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NERV. Analyze the recent business situations of Minerva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NERV stock price target is 7.00 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 126
Institutional Holdings: 39.82M
% Owned: 93.22%
Shares Outstanding: 42.72M
TypeInstitutionsShares
Increased
17
2.29M
New
14
599.64K
Decreased
26
6.29M
Sold Out
19
804.53K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Remy Luthringer
Chief Financial Officer/Executive Vice President
Geoffrey Race
Chief Operating Officer/Senior Vice President
Joseph Reilly
Senior Vice President/Chief Accounting Officer
Frederick Ahlholm
Senior Vice President/General Counsel
Devin Smith
Senior Vice President
Jay Saoud
Other
Michael Davidson
Lead Director/Independent Director
William Doyle
Independent Director
Hans Hasler
Independent Director
Jeryl Hilleman
Independent Director
David Kupfer
Independent Director
Fouzia Laghrissi-Thode
Independent Director
Jan van Heek
No Data
  • All
  • Financials
  • Insiders
More
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Webull offers kinds of Minerva Neurosciences Inc stock information, including NASDAQ:NERV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NERV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NERV stock methods without spending real money on the virtual paper trading platform.